Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Cited by (1,051)

Items 701–800 of 1,051

1. The M2 macrophage marker CD206 : a novel prognostic indicator for acute myeloid leukemia
   Zi‐jun Xu, Yu Gu, Cuizhu Wang, Ye Jin, Xiang‐mei Wen, Ji‐chun Ma, Li‐Juan Tang, Zhen-Wei Mao, Jun Qian, Jiang Lin · 2019 · OncoImmunology
2. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
   Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George Jabboure Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle et al. · 2016 · Cancer Immunology Research
3. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
   Badi Edmond El Osta, Fangyuan Hu, Reem Ahmed Sadek, Rohini Chintalapally, Shou Ching Tang · 2017 · Critical Reviews in Oncology/Hematology
4. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
   Sibylle C. Mellinghoff, Jens Panse, Nael Alakel, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Justin Hasenkamp, Michael G Kiehl, Michael Koldehoff, Stefan W. Krause et al. · 2017 · Annals of Hematology
5. Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
   Neus Martínez‐Bosch, Judith Vinaixa, Pilar Navarro · 2018 · Cancers
6. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients
   Xu‐Chao Zhang, Jun Wang, Guoguang Shao, Qun Wang, Xiaotao Qu, Bo Wang, Christopher H. Moy, Yue Fan, Zayed Albertyn, Xiayu Huang et al. · 2019 · Nature Communications
7. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
   Bin Zhao, Hong Zhao, Jiaxin Zhao · 2020 · Therapeutic Advances in Medical Oncology
8. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy
   Zhibin Wang, Xiu Zhang, Chao Fang, Xiaoting Liu, Qianjin Liao, Nayiyuan Wu, Jing Wang · 2024 · Immunology
9. PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
   Zhiqiang Guo, Xin Wang, Dali Cheng, Zhijun Xia, Meng Luan, Shulan Zhang · 2014 · PLoS ONE
10. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function
    Ruihua Zhao, Jordan M. Chinai, Susan Buhl, Lisa Scandiuzzi, Anjana Ray, Hyungjun Jeon, Kim C. Ohaegbulam, Kaya Ghosh, Aimin Zhao, Matthew D. Scharff et al. · 2013 · Proceedings of the National Academy of Sciences
11. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery
    Jae Woo Lee, Chad A. Komar, Fee Bengsch, Kathleen L. Graham, Gregory Lawrence Beatty · 2016 · Current Protocols in Pharmacology
12. Immune checkpoint inhibitors: The linchpins of modern immunotherapy
    Breelyn Ann Wilky · 2019 · Immunological Reviews
13. Regulation and modulation of antitumor immunity in pancreatic cancer
    Joshua Leinwand, George Miller · 2020 · Nature Immunology
14. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
    Gunjan Dagar, Ashna Gupta, Tariq Masoodi, Sabah Nisar, Maysaloun Merhi, Sheema Hashem, Ravi Chauhan, Manisha Dagar, Sameer Mirza, Puneet Bagga et al. · 2023 · Journal of Translational Medicine
15. Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
    Philipp Müller, Kea Martin, Sebastian Theurich, Jens Schreiner, Spasenija Savic, Grzegorz Terszowski, Didier Lardinois, Viola A Heinzelmann-Schwarz, Max S. Schlaak, Hans Michael Kvasnicka et al. · 2014 · Cancer Immunology Research
16. Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
    Olga K. Afanasiev, Lola Yelistratova, Natalie J. Miller, Kotaro Nagase, Kelly Garneski Paulson, Jayasri G. Iyer, Dafina Ibrani, David M. Koelle, Paul Nghiem · 2013 · Clinical Cancer Research
17. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma
    Minwei Yang, Ling‐Ye Tao, Yongsheng Jiang, Jian‐Yu Yang, Yan‐Miao Huo, Dejun Liu, Jiao Li, Xueliang Fu, Ruizhe He, Chaoyi Lin et al. · 2020 · Cancer Research
18. RETRACTED: Nanoscale Metal-Organic Framework Mediates Radical Therapy to Enhance Cancer Immunotherapy
    Kaiyuan Ni, Theint Aung, Shuyi Li, Nina Fatuzzo, Xing‐Jie Liang, Wenbin Lin · 2019 · Chem · Retracted
19. Sarcomatoid renal cell carcinoma: biology, natural history and management
    Kyle A. Blum, Sounak Gupta, Satish K. Tickoo, Timothy An-thy Chan, Paul Russo, Robert John Motzer, Jose Antonio Karam, A. Ari Hakimi · 2020 · Nature Reviews Urology
20. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
    Chin-King Looi, Felicia Fei‐Lei Chung, Chee‐Onn Leong, Shew Fung Wong, Rozita Rosli, Chun‐Wai Mai · 2019 · Journal of Experimental & Clinical Cancer Research
21. Immune-suppressive properties of the tumor microenvironment
    Jürgen Christian Becker, Mads Hald Andersen, David Schrama, Per thor Straten · 2013 · Cancer Immunology Immunotherapy
22. Current progress in immunotherapy for pancreatic cancer
    Kelly Foley, Victoria Kim, Elizabeth M. Jaffee, Lei Zheng · 2015 · Cancer Letters
23. PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens
    Jonas J. Heymann, William A. Bulman, David Swinarski, Carlos A. Pagan, John P. Crapanzano, Mehrvash Haghighi, Ladan Fazlollahi, Mark B. Stoopler, Joshua R. Sonett, Adrian G. Sacher et al. · 2017 · Cancer Cytopathology
24. Drug-Induced Sarcoidosis-Like Reactions
    Amit Chopra, Amit Nautiyal, Alexandros Kalkanis, Marc A. Judson · 2018 · CHEST Journal
25. Gene editing for immune cell therapies
    Stefanie R. Bailey, Marcela Valderrama Maus · 2019 · Nature Biotechnology
26. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
    Abhisek Swaika, William A. Hammond, Richard Wayne Joseph · 2015 · Molecular Immunology
27. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
    David F. McDermott, Célèste Lebbé, Frank Stephen Hodi, Michele Maio, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson, Charles M. Balch · 2014 · Cancer Treatment Reviews
28. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
    Xin Li, Yasong Cheng, Mingzhi Zhang, Jiaqin Yan, Ling Li, Xiaorui Fu, Xudong Zhang, Yu Chang, Zhenchang Sun, Hui Yu et al. · 2018 · Journal of Hematology & Oncology
29. Immunotherapy for glioblastoma: the promise of combination strategies
    Mathilde Bausart, Véronique Préat A, Alessio Malfanti · 2022 · Journal of Experimental & Clinical Cancer Research
30. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
    Ingunn M. Stromnes, Thomas M. Schmitt, Ayaka Hulbert, J. Scott Brockenbrough, Hieu Nguyen, Carlos Mario Cuevas, Ashley Dotson, Xiaoxia Tan, Jennifer L. Hotes, Philip D. Greenberg et al. · 2015 · Cancer Cell
31. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
    Sébastien Le Burel, Stéphane Champiat, Christine Mateus, Aurélien Marabelle, Jean‐Marie Michot, Caroline Robert, Rakiba Belkhir, Jean‐Charles Soria, Salim Laghouati, Anne-Laure Voisin et al. · 2017 · European Journal of Cancer
32. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
    Ingunn M. Stromnes, Ayaka Hulbert, Robert Hamilton Pierce, Philip D. Greenberg, Sunil R. Hingorani · 2017 · Cancer Immunology Research
33. Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
    Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal, María Jesús García-Granda, María Gato, Ana Bocanegra, Berta Hernández, Maite Martínez, Lucía Teijeira, Idoia Morilla et al. · 2019 · EMBO Molecular Medicine
34. Acquired and intrinsic resistance in cancer immunotherapy
    Kelderman, Sander, Schumacher, Ton N.M., Haanen, John B.A.G. · 2014 · Molecular Oncology
35. Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
    Siwen Hu‐Lieskovan, Lídia Robert, Blanca Homet Moreno, Antoni Ribas · 2014 · Journal of Clinical Oncology
36. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
    Konstantinos E. Georgiou, Longyun Chen, Mattias Berglund, Weicheng Ren, Noel F.C.C. de Miranda, Susana Lisboa, Marco Fangazio, Shida Zhu, Yong Hou, Kui Wu et al. · 2016 · Blood
37. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
    Shuhang Wang, Stella T. Tsui, Christina Liu, Yongping Song, Delong Liu · 2016 · Journal of Hematology & Oncology
38. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
    Cassandra M. Calabrese, E Kirchner, Apostolos Kontzias, Vamsidhar Velcheti, Leonard H. Calabrese · 2017 · RMD Open
39. A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
    Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish Ramesh Patel, Holbrook E K Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary Lenora Disis, Judith C. Kaiser et al. · 2017 · Clinical Cancer Research
40. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
    Hongshu Sui, Ningxia Ma, Ying Wang, Hui Li, Xiaoming Liu, Yanping Su, Jiali Yang · 2018 · Journal of Immunology Research
41. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
    A. Oliveira, Luís Bretes, Irene Furtado · 2019 · Frontiers in Oncology
42. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation
    Vendetti, Frank P., Karukonda, Pooja, Clump, David A., Teo, Troy, Lalonde, Ronald, Nugent, Katriana, Ballew, Matthew, Kiesel, Brian F., Beumer, Jan H., Sarkar, Saumendra N. et al. · 2018 · Journal of Clinical Investigation
43. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
    Carmen Herling, Nima Abedpour, Jonathan M. Weiss, Anna Schmitt, Ron Daniel Jachimowicz, Olaf Merkel, Maria Cartolano, Sebastian Oberbeck, Petra Mayer, Valeska Berg et al. · 2018 · Nature Communications
44. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
    Xi Chen, Xiaohui Pan, Wenxin Zhang, Hongjie Guo, Shuyuan Cheng, Qiaojun He, Bo Yang, Ling Ding · 2019 · Acta Pharmaceutica Sinica B
45. Cancer Vaccines, Adjuvants, and Delivery Systems
    Paston, Samantha J., Brentville, Victoria A., Symonds, Peter, Durrant, Lindy G. · 2021 · Frontiers in Immunology
46. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
    Lee, Lik Hang, Cavalcanti, Marcela S, Segal, Neil H, Hechtman, Jaclyn F, Weiser, Martin R, Smith, J Joshua, Garcia-Aguilar, Julio, Sadot, Eran, Ntiamoah, Peter, Markowitz, Arnold J et al. · 2016 · Modern Pathology
47. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB–Mediated Production of CXCL1
    Kemp, Samantha B., Carpenter, Eileen S., Steele, Nina G., Donahue, Katelyn L., Nwosu, Zeribe C., Pacheco, Amanda, Velez-Delgado, Ashley, Menjivar, Rosa E., Lima, Fatima, The, Stephanie et al. · 2021 · Cancer Research
48. Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
    Lussier, Danielle M., O’Neill, Lauren, Nieves, Lizbeth M., McAfee, Megan S., Holechek, Susan A., Collins, Andrea W., Dickman, Paul, Jacobsen, Jeffrey, Hingorani, Pooja, Blattman, Joseph N. · 2015 · Journal of Immunotherapy
49. Predictors of responses to immune checkpoint blockade in advanced melanoma
    Nicolas Jacquelot, María P. Roberti, David Pierre Enot, Sylvie Rusakiewicz, Nils Ternès, S. Jegou, David Michael Woods, Andressa L. Sodré, Morten Hansen, Yaron Meirow et al. · 2017 · Nature Communications
50. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences
    Nikko Brix, Anna Tiefenthaller, Heike Anders, Claus Belka, Kirsten Lauber · 2017 · Immunological Reviews
51. Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
    Huizhong Xiong, Stephanie Mittman, Ryan Rodriguez, Марина Москаленко, Patricia Pacheco-Sanchez, Yagai Yang, Dorothee Nickles, Rafael A. Cubas · 2019 · Cancer Research
52. The Immune Subtypes and Landscape of Squamous Cell Carcinoma
    Bailiang Li, Yi Cui, Dhanya K. Nambiar, John B. Sunwoo, Ruijiang Li · 2019 · Clinical Cancer Research
53. Pancreatic cancer treatment: better, but a long way to go
    Robert J. Torphy, Yuki Fujiwara, Richard David Schulick · 2020 · Surgery Today
54. <i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
    Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy et al. · 2020 · Blood
55. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
    Howard L. Kaufman, John M. Kirkwood, Frank Stephen Hodi, Sanjiv S. Agarwala, THOMAS T. AMATRUDA, Steven D. Bines, Joseph I. Clark, Brendan D. Curti, Marc S. Ernstoff, Thomas Frank Gajewski et al. · 2013 · Nature Reviews Clinical Oncology
56. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
    Richard Wayne Joseph, Sherri Z. Millis, Estrella M. Carballido, David H. Bryant, Zoran Gatalica, Sandeep K. Reddy, Alan Haruo Bryce, Nicholas J. Vogelzang, Melissa Stanton, Erik P. Castle et al. · 2015 · Cancer Immunology Research
57. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
    Daniel R. Principe, Brian T. DeCant, Emman Mascariñas, Elizabeth A. Wayne, Andrew M. Diaz, Naomi Akagi, Rosa F. Hwang, Boris Pasche, David W. Dawson, Deyu Fang et al. · 2016 · Cancer Research
58. Resistance mechanisms to immune checkpoint inhibitors: updated insights
    Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Molecular Cancer
59. Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
    Fabrice André, Maria Vittoria Dieci, Peter Christian Dubsky, Christos P. Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi · 2012 · Clinical Cancer Research
60. The role of imaging in the management of progressive glioblastoma
    Timothy Charles Ryken, Nafi Aygün, Johnathan Morris, Marin Leigh Schweizer, Rajeshwari Nair, Cassandra Nichole Spracklen, Steven N. Kalkanis, Jeffrey J. Olson · 2014 · Journal of Neuro-Oncology
61. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
    Erhao Zhang, Hanmei Xu · 2017 · Journal of Hematology & Oncology
62. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors
    Ioannis Gkiozos, Alexandra Kopitopoulou, Alexandros Kalkanis, Ioannis N. Vamvakaris, Marc A. Judson, Konstantinos Nikolaos Syrigos · 2018 · Journal of Thoracic Oncology
63. A Nanoscale Metal–Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy
    Kaiyuan Ni, Taokun Luo, Guangxu Lan, August A. Culbert, Yang Song, Tong Wu, Xiaomin Jiang, Wenbin Lin · 2019 · Angewandte Chemie International Edition
64. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
    Hendry, Shona A., Farnsworth, Rae H., Solomon, Benjamin, Achen, Marc G., Stacker, Steven A., Fox, Stephen B. · 2016 · Frontiers in Immunology
65. Engineered skin bacteria induce antitumor T cell responses against melanoma
    Chen, Y. Erin, Bousbaine, Djenet, Veinbachs, Alessandra, Atabakhsh, Katayoon, Dimas, Alex, Yu, Victor K., Zhao, Aishan, Enright, Nora J., Nagashima, Kazuki, Belkaid, Yasmine et al. · 2023 · Science
66. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
    Samit Chatterjee, Wojciech G. Lesniak, Matthew Gabrielson, Ala Lisok, Bryan L. Wharram, Polina Sysa‐Shah, Babak Behnam Azad, Martin G. Pomper, Sridhar Nimmagadda · 2016 · Oncotarget
67. Reprogramming the immunological microenvironment through radiation and targeting Axl
    Todd Anthony Aguilera, Marjan Rafat, Laura Castellini, Hussein Shehade, Mihalis S. Kariolis, Angela Bik‐Yu Hui, Henning Stehr, Rie von Eyben, Dadi Jiang, Lesley G. Ellies et al. · 2016 · Nature Communications
68. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
    Masatoshi Kudo · 2017 · Oncology
69. Programmed Cell Death Ligand 1 Expression in Osteosarcoma
    Jacson K. Shen, Gregory Michael Cote, Edwin Choy, Pei Yang, David C. Harmon, Joseph Hasbrouck Schwab, G. Petur Nielsen, Ivan A. Chebib, Soldano Ferrone, Xinhui Wang et al. · 2014 · Cancer Immunology Research
70. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
    Zheng Wang, Chuanbao Zhang, Xing Liu, Zhiliang Wang, Lihua Sun, Guanzhang Li, Jingshan Liang, Huimin Hu, Yanwei Liu, Wei Zhang et al. · 2016 · OncoImmunology
71. A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer
    Bryan T. Oronsky, Carolyn M. Ray, Alexander I. Spira, Jane B. Trepel, Corey Allan Carter, Hope M. Cottrill · 2017 · Medical Oncology
72. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer
    Qiqing Sun, Bo Zhang, Qiangsheng Hu, Yi Qin, Wenyan Xu, Wensheng Liu, Xianjun Yu, Jin Xu · 2018 · Theranostics
73. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells
    Laia Gorchs, Carlos Fernández Moro, Peter Bankhead, Katharina P. Kern, Imrul Sadeak, Qingda Meng, Elena B. Rangelova, Helen Kaipe · 2019 · Frontiers in Immunology
74. Exomics and immunogenics
    Stéphane Champiat, Charles Ferté, Sophie Lebel‐Binay, Alexander M.M. Eggermont, Jean‐Charles Soria · 2014 · OncoImmunology
75. Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
    Courtney A. Crane, Seunggu Jude Han, Brian J. Ahn, Jessica Oehlke, Valerie A Kivett, Anne Fedoroff, Nicholas Arthur Butowski, Susan Marina Chang, Jennifer Leigh Clarke, Mitchel Stuart Berger et al. · 2012 · Clinical Cancer Research
76. Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
    Laura Jeanbart, Marie Christine Ballester, Alexandre de Titta, Patricia Corthésy, Pedro J. Romero, Jeffrey A. Hubbell, Melody A. Swartz · 2014 · Cancer Immunology Research
77. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
    Miguel F. Sanmamed, Fernando Pastor, Alfonso R. Sánchez-Paulete, José Luis Perez‐Gracia, Maria Esperanza Rodriguez-Ruiz, Maria Jure‐Kunkel, Ignacio Melero · 2015 · Seminars in Oncology
78. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway
    Meimiao Zhan, Xueqin Hu, Xiu-Xiu Liu, Ban‐Feng Ruan, Jun Xu, Chenzhong Liao · 2016 · Drug Discovery Today
79. Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer
    Fang Zhen Sun, Qiurong Zhu, Tianliang Li, Madiha Saeed, Zhiai Xu, Feisheng Zhong, Rundi Song, Manxiu Huai, Mingyue Zheng, Cen Xie et al. · 2021 · Advanced Science
80. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy
    Ziyi Bai, Yao Zhou, Zifan Ye, Jialong Xiong, Hongying Lan, Feng Wang · 2022 · Frontiers in Immunology
81. Targeted antibody and cytokine cancer immunotherapies through collagen affinity
    Ishihara, Jun, Ishihara, Ako, Sasaki, Koichi, Lee, Steve Seung-Young, Williford, John-Michael, Yasui, Mariko, Abe, Hiroyuki, Potin, Lambert, Hosseinchi, Peyman, Fukunaga, Kazuto et al. · 2019 · Science Translational Medicine
82. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    Sergio A. Quezada, Karl S. Peggs · 2013 · British Journal of Cancer
83. Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
    Julie Renee Brahmer, Drew M. Pardoll · 2013 · Cancer Immunology Research
84. Impact of the immune system and immunotherapy in colorectal cancer.
    Janet L. Markman, Stephen Lawrence Shiao · 2015 · PubMed Central
85. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
    Emeka K. Enwere, Elizabeth N. Kornaga, Michelle Liane Dean, Theodora A. Koulis, Tien Phan, Maria Kalantarian, Martin Köbel, Prafull Ghatage, Anthony M. Magliocco, Susan P. Lees‐Miller et al. · 2017 · Modern Pathology
86. Genomic ERBB2 / ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
    Maolan Li, Fatao Liu, Fei Zhang, Weiping Zhou, Xiaoqing Jiang, Yuan Yang, Kai Qu, Yueqi Wang, Qiang Ma, Ting Wang et al. · 2018 · Gut
87. Multidisciplinary approach of liver metastases from colorectal cancer
    René A. Adam, Yuki Kitano · 2019 · Annals of Gastroenterological Surgery
88. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
    Julia Kargl, Xiaodong Zhu, Huajia Zhang, Grace H. Y. Yang, Travis J. Friesen, Melissa Shipley, Dean Y. Maeda, John A. Zebala, Jill McKay-Fleisch, Gavin D. Meredith et al. · 2019 · JCI Insight
89. Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
    Andreas Due Ørskov, Marianne Bach Treppendahl, Anni Skovbo, Mette Skov Holm, Lone Smidstrup Friis, Marianne Hokland, Kirsten Grønbæk · 2015 · Oncotarget
90. New immunotherapies targeting the PD-1 pathway
    Jordan M. Chinai, Murali Janakiram, Fuxiang Chen, Wantao Chen, Mark Kaplan, Xingxing Zang · 2015 · Trends in Pharmacological Sciences
91. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
    Howard Y. Li, Maria V. McSharry, Bonnie Bullock, Teresa T. Nguyen, Jeff Kwak, Joanna M. Poczobutt, Trisha R. Sippel, Lynn E. Heasley, Mary C. M. Weiser-Evans, Eric T. Clambey et al. · 2017 · Cancer Immunology Research
92. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
    Rehan Ahmad, Jaikee Kumar Singh, Amoolya Wunnava, Omar Abdullah Al-Obeed, Maha‐Hamadien Abdulla, Sandeep Kumar Srivastava · 2021 · International Journal of Molecular Medicine
93. The role of B7 family molecules in hematologic malignancy
    Paul Greaves, John G. Gribben · 2012 · Blood
94. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
    Takaaki Tokito, Koichi Azuma, Akihiko Kawahara, Hidenobu Ishii, Kazuhiko Yamada, Norikazu Matsuo, Takashi Kinoshita, Naohisa Mizukami, Hirofumi Ono, Masayoshi Kage et al. · 2016 · European Journal of Cancer
95. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
    Jin Sheng, Wenfeng Fang, Juan Yu, Nan Chen, Jianhua Zhan, Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Li Zhang · 2016 · Scientific Reports
96. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain
    Kaiyuan Wang, Yun Gu, Yihan Liao, Sangsu Bang, Christopher R. Donnelly, Chen Ouyang, Xueshu Tao, Anthony J. Mirando, Matthew J. Hilton, Ru‐Rong Ji · 2020 · Journal of Clinical Investigation
97. Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
    Norman Woller, Engin Gürlevik, Bettina Fleischmann-Mundt, Anja Schumacher, Sarah Knocke, Arnold Kloos, Michael Saborowski, Robert Geffers, Michael Peter Manns, Thomas Christian Wirth et al. · 2015 · Molecular Therapy
98. Neurologic complications of immune checkpoint inhibitors
    Alexandra M. Haugh, John C. Probasco, Douglas Buckner Johnson · 2020 · Expert Opinion on Drug Safety
99. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
    Yago Pico de Coaña, Aniruddha Choudhury, Rolf W. Kiessling · 2015 · Trends in Molecular Medicine
100. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
     Moon‐Young Kim, Jaemoon Koh, Sehui Kim, Heounjeong Go, Yoon Kyung Jeon, Doo Hyun Chung · 2015 · Lung Cancer